Home » Topics » Conferences

Conferences
RSS

Non-steroidal compounds for postmenopausal disorders described by Lilly

July 12, 1996

Potent tyrosine kinase inhibitors derived from PD-089828

July 12, 1996

Protein farnesyltransferase inhibitor in Warner-Lambert's compound library

July 12, 1996

PD-158780: A potent and selective EGF tyrosine kinase inhibitor

July 12, 1996

SB-210313: A potent LPS-TNF production inhibitor

July 12, 1996

AIDS Research Highlights (July 7-12, Vancouver)

July 12, 1996

U-94901: A powerful antibacterial agent from Pharmacia & Upjohn

July 12, 1996

EGCg shows antibacterial properties against H. pylori

June 28, 1996

Adenosine A3 antagonists from Merck & Co.

June 28, 1996

TV-1901 demonstrates efficiency and safety

June 28, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...